Related Experiment Video
Updated: Jun 24, 2025

Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis
Jiajun Yu1,2, Bo Long3, Ziyong Li1,2
1School of Medicine, Chongqing University, Chongqing 400030, China.
Insights
Immune checkpoint inhibitors (ICIs) can cause myocarditis. This study found that CD4+ TCM cells protect the heart during ICI therapy. Targeting IL-15, IL-4I1, and CD4+ TCM cells may prevent ICI-associated myocarditis.
Area of Science:
- Immunology
- Oncology
- Cardiology
Background:
- Immune checkpoint inhibitors (ICIs) improve cancer survival but can cause immune-related adverse events.
- ICI-associated myocarditis is a rare but severe complication with high mortality.
- Understanding the mechanisms of ICI-associated myocarditis is crucial for patient safety.
Purpose of the Study:
- To investigate the immune cell subsets and inflammatory factors involved in ICI-associated myocarditis.
- To elucidate the role of CD4+ T central memory (TCM) cells in cardiac protection during ICI therapy.
- To identify potential therapeutic targets for preventing ICI-associated myocarditis.
Main Methods:
- Analysis of peripheral blood immune cells and inflammatory factors in patients and mice undergoing ICI therapy.
- RNA sequencing of CD4+ TCM cells to identify immunosuppressive factors.
- Protein array analysis to assess inflammatory factor levels.
- In vivo studies using anti-PDL1 antibody and IL-15 in a mouse tumor model.
Main Results:
- ICI-associated myocarditis was linked to increased NK and myeloid cells, decreased T cells, and an imbalanced CD4/CD8 ratio, with reduced CD4+ TCM cells.
- CD4+ TCM cells in myocarditis patients expressed the immunosuppressive factor IL-4I1.
- Decreased IL-15 and increased inflammatory factors (IL-1B, CXCL13, CXCL9) correlated with myocarditis severity.
- In mice, anti-PDL1 treatment reduced CD4+ TCM cells and increased cardiac fibrosis; IL-15 administration restored CD4+ TCM cells and mitigated fibrosis.
Conclusions:
- CD4+ TCM cells play a critical role in cardiac protection during ICI therapy.
- IL-15, IL-4I1, and CD4+ TCM cells are potential therapeutic targets for mitigating ICI-associated myocarditis.
- Targeting these factors could improve the safety of ICI therapy for cancer patients.
Aims:
The widespread use of immune checkpoint inhibitors (ICIs) has demonstrated significant survival benefits for cancer patients and also carries the risk of immune-related adverse events. ICI-associated myocarditis is a rare and serious adverse event with a high mortality rate. Here, we explored the mechanism underlying ICI-associated myocarditis.
Methods And Results:
Using the peripheral blood of patients with ICI therapy and of ICI-treated mice with transplanted tumours, we dissect the immune cell subsets and inflammatory factors associated with myocarditis. Compared to the control group, patients with myocarditis after ICI therapy showed an increase in NK cells and myeloid cells in the peripheral blood, while T cells significantly decreased. Among T cells, there was an imbalance of CD4/CD8 ratio in the peripheral blood of myocarditis patients, with a significant decrease in central memory CD4+ T (CD4+ TCM) cells. RNA sequencing revealed that CD4+ TCM cells in myocarditis patients were immunosuppressive cell subsets, which highly express the immunosuppressive factor IL-4I1. To elucidate the potential mechanism of the decrease in CD4+ TCM cells, protein array was performed and revealed that several inflammatory factors gradually increased with the severity of myocarditis in the myocarditis group, such as IL-1B/CXCL13/CXCL9, while the myocardial protective factor IL-15 decreased. Correlation analysis indicated a positive correlation between IL-15 and CD4+ TCM cells, with high expression of IL-15 receptor IL15RA. Furthermore, in vivo studies using an anti-PDL1 antibody in a mouse tumour model indicated a reduction in CD4+ TCM cells and an increase in effector memory-expressing CD45RA CD8+ T (TEMRA) cells, alongside evidence of cardiac fibrosis. Conversely, combining anti-PDL1 antibody treatment with IL-15 led to a resurgence of CD4+ TCM cells, a reduction in CD8+ TEMRA cells, and a mitigated risk of cardiac fibrosis.
Conclusion:
Our data highlight CD4+ TCM cells' crucial role in cardiac protection during ICI therapy. IL-15, IL-4I1, and CD4+ TCM cells can serve as therapeutic targets to reduce ICI-associated myocarditis in cancer patients.
Related Concept Videos
Cell-mediated Immune Responses
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

